European Association for the Study of Diabetes
European Association for the Study of Diabetes
September 26, 2013
1 min read
Save

Six biomarkers linked to prediction of CVD in type 2 diabetes

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Researchers have confirmed associations between six biomarkers for the prediction of cardiovascular disease in type 2 diabetes, according to data presented at EASD 2013.

“We’re also reporting what we think is a novel association between interleukin-15 as a predictor of incident CVD in type 2 diabetes and these interesting associations of apolipoprotein C-III and soluble RAGE (sRAGE) with incident CVD, which were unexpected and need further investigation,” Helen C. Looker, MBBS, of the National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, said during a presentation.

The study included patients with type 2 diabetes from the Go-DARTS (n=1,204), the Scania Diabetes Registry (n=666), MONICA/KORA (n=308), IMPROVE (n=94) and 60-year Old Stockholm Study (n=64), according to abstract data.

Looker and colleagues examined 42 biomarkers, but only 16 were studied further for their improved prediction of CVD.

“Of the biomarkers we tested, many showed association with incident CVD, but when picking a panel, we found most of the improvement in prediction could be cut down to six markers in addition to clinical covariates,” Looker said

Those with the most significant association with CVD included:

  • N-terminal pro-B-type natriuretic peptide (OR=1.72; 95% CI, 1.49-1.99);
  • Apolipoprotein C-III (OR=1.26; 95% CI, 1.10-1.43);
  • sRAGE (OR=0.82; 95% CI, 0.73-0.91);
  • High-sensitivity troponin T (OR=0.85; 95% CI, 0.77-0.94);
  • IL-6 (OR=1.16; 95% CI, 1.05-1.29); and
  • IL-15 (OR=1.17; 95% CI, 1.06-1.29).

“We feel these findings are already relatively robust because they’ve been found across several studies, but we clearly need to do some replication in other cohorts, and that is ongoing,” Looker said.

For more information:

Brady I. Oral Presentation #9. Presented at: the 49th Annual Meeting of the European Association for the Study of Diabetes; Sept. 24-27, 2013; Barcelona, Spain.

Disclosure: This study was supported by SUMMIT Consortium IMI-2008/115006 and Hoffmann-La Roche.